Natixis Advisors LLC Has $851,000 Stock Holdings in Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE)

Natixis Advisors LLC cut its holdings in shares of Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE - Free Report) by 53.8% during the first quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 23,506 shares of the biopharmaceutical company's stock after selling 27,404 shares during the period. Natixis Advisors LLC's holdings in Ultragenyx Pharmaceutical were worth $851,000 at the end of the most recent reporting period.

A number of other hedge funds have also modified their holdings of RARE. GAMMA Investing LLC lifted its holdings in Ultragenyx Pharmaceutical by 76.2% in the first quarter. GAMMA Investing LLC now owns 747 shares of the biopharmaceutical company's stock valued at $27,000 after acquiring an additional 323 shares during the period. ANTIPODES PARTNERS Ltd purchased a new stake in Ultragenyx Pharmaceutical in the 1st quarter valued at about $57,000. GF Fund Management CO. LTD. purchased a new stake in Ultragenyx Pharmaceutical in the 4th quarter valued at about $82,000. Quarry LP purchased a new stake in shares of Ultragenyx Pharmaceutical during the 4th quarter worth about $84,000. Finally, Quantinno Capital Management LP purchased a new position in Ultragenyx Pharmaceutical in the 4th quarter worth approximately $211,000. 97.67% of the stock is currently owned by hedge funds and other institutional investors.

Insider Buying and Selling at Ultragenyx Pharmaceutical

In related news, Director Corazon (Corsee) D. Sanders sold 2,405 shares of the stock in a transaction that occurred on Friday, June 20th. The stock was sold at an average price of $37.39, for a total transaction of $89,922.95. Following the completion of the transaction, the director directly owned 15,344 shares of the company's stock, valued at approximately $573,712.16. This represents a 13.55% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. 5.50% of the stock is owned by corporate insiders.

Ultragenyx Pharmaceutical Price Performance

Shares of Ultragenyx Pharmaceutical stock traded up $0.66 during midday trading on Friday, hitting $29.67. 201,904 shares of the company were exchanged, compared to its average volume of 1,290,164. The firm has a market cap of $2.86 billion, a P/E ratio of -5.36 and a beta of 0.25. Ultragenyx Pharmaceutical Inc. has a 52 week low of $25.81 and a 52 week high of $60.37. The firm has a 50 day simple moving average of $32.67 and a 200-day simple moving average of $36.35.

Ultragenyx Pharmaceutical (NASDAQ:RARE - Get Free Report) last released its earnings results on Tuesday, August 5th. The biopharmaceutical company reported ($1.17) earnings per share for the quarter, topping analysts' consensus estimates of ($1.27) by $0.10. Ultragenyx Pharmaceutical had a negative return on equity of 237.48% and a negative net margin of 87.34%. The company had revenue of $166.50 million during the quarter, compared to the consensus estimate of $161.37 million. During the same quarter in the previous year, the company posted ($1.52) earnings per share. The firm's quarterly revenue was up 13.2% on a year-over-year basis. Equities research analysts expect that Ultragenyx Pharmaceutical Inc. will post -5.18 earnings per share for the current year.

Wall Street Analysts Forecast Growth

Several research firms recently issued reports on RARE. Canaccord Genuity Group cut their price target on shares of Ultragenyx Pharmaceutical from $136.00 to $128.00 and set a "buy" rating on the stock in a report on Friday, August 8th. Wedbush dropped their price target on Ultragenyx Pharmaceutical from $35.00 to $34.00 and set a "neutral" rating on the stock in a research report on Monday, July 14th. Guggenheim reissued a "buy" rating and set a $64.00 price target on shares of Ultragenyx Pharmaceutical in a research report on Friday, June 20th. Wells Fargo & Company dropped their target price on Ultragenyx Pharmaceutical from $88.00 to $65.00 and set an "overweight" rating on the stock in a research report on Thursday, July 10th. Finally, Cantor Fitzgerald dropped their target price on Ultragenyx Pharmaceutical from $112.00 to $105.00 and set an "overweight" rating on the stock in a research report on Wednesday, August 6th. One analyst has rated the stock with a hold rating and eleven have issued a buy rating to the company's stock. According to MarketBeat, Ultragenyx Pharmaceutical has an average rating of "Moderate Buy" and an average price target of $81.50.

Ultragenyx Pharmaceutical Profile

Ultragenyx Pharmaceutical Inc, a biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of novel products for the treatment of rare and ultra-rare genetic diseases in North America, Latin America, Japan, Europe, and internationally. Its biologic products include Crysvita (burosumab), an antibody targeting fibroblast growth factor 23 for the treatment of X-linked hypophosphatemia, as well as tumor-induced osteomalacia; Mepsevii, an enzyme replacement therapy for the treatment of children and adults with Mucopolysaccharidosis VII; Dojolvi for treating long-chain fatty acid oxidation disorders; and Evkeeza (evinacumab) for the treatment of homozygous familial hypercholesterolemia.